Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878436 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00878436 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 52 participants.
The verdict
NCT00878436, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer. This trial is at its Phase II stage. As of July 23, 2013 Arm B was closed to accrual, all the remaining slots in accrual will be allocated to Arm A.
Interventions
- DRUG Bicalutamide
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878436
The ClinicalTrials.gov registry entry for NCT00878436 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bicalutamide is the first listed.
NCT00878436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878436 about?
NCT00878436 is a clinical study titled "Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration". This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat (a histone deacetylase inhibitor) and hormone therapy for recurrent prostate cancer. This trial is at its Phase II stage. As of July 23, 2013 Arm B was closed to accrual, all ...
What is the current status of trial NCT00878436?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2009-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00878436?
The interventions under investigation include: Bicalutamide (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00878436?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.